Poster Presentation 2025 Joint Meeting of the COSA ASM and IPOS Congress

CUPID: Transforming Cancer of Unknown Primary with Intelligent Diagnostics (126788)

Christos S Karapetis 1 , Abigail Miller 2 , Tiffany Foo 2 , Alex Brown 3 , Justine Clark 4 , Claire Vajdic 5 , Anna Brown 6 7 , Hamish Scott 6 8 , Daniel Thomas 6 , Greg Pratt 9 , Richard Tothill 10 , Sean Grimmond 10 , Ifrah Hasan 2 , Rebbecca Cato 2 , Nadia Corsini 11 , Michael Cilento 2 , Zarina Greenberg 12 , Matthew Links 13 , Ganessan Kichenadasse 1
  1. Flinders University and Flinders Medical Centre, Bedford Park, SA, Australia
  2. Flinders Centre for Innovation in Cancer, Bedford Park, SA, Australia
  3. ANU, Canberra
  4. The Kids Research Institute, Adelaide
  5. University of NSW, Sydney
  6. University of Adelaide, Adelaide, SA
  7. SA Pathology, Adelaide
  8. SA Pathology, Adelaide
  9. Central Queensland University, Brisbane
  10. University of Melbourne, Melbourne
  11. University of SA, Adelaide
  12. SAHMRI, Adelaide
  13. Alice Springs Hospital, Alice Springs

Background

Cancer of Unknown Primary (CUP) is a metastatic cancer with no identified primary site. Comprehensive genomic profiling (CGP) and tissue of origin (TOO) genomic testing of CUP has potential to guide therapy. The Australian Optimal Care Pathway (OCP) for CUP, released in January 2020, was developed to improve care and outcomes for patients with CUP. The CUPID study (ACTRN12623001221640) is an MRFF funded clinical trial being conducted across SA and NT (MRFF Grant ID 2007652).

 

Aims

To determine the clinical impact of CGP and TOO testing 

To examine CUP among Indigenous Australians

To estimate health service use & health care system costs through data linkage

To evaluate clinical practice benchmarked to the OCP

To evaluate patterns of care over a 20-year period

To characterise metabolomic signatures 

To establish a molecular multidisciplinary team meeting in SA


Methods

Prospective trial: A multicentre prospective observational cohort study, with all CUP patients at participating sites invited to participate. CGP and TOO genomic analysis will be performed to attempt to identify a primary site and match to appropriate targeted therapies.

Retrospective study: Data from 1 January 2000 to 31 December 2022 will be retrospectively collected. with plans to analyse of patterns of care over time and clinical outcomes.

Indigenous research: A separate Aboriginal sub-study protocol has been developed to support Aboriginal access to, and benefit from, the CUPID study. An Aboriginal Care Coordinator will support Aboriginal patients. Patient interviews will be conducted to define benefits of care coordination and experiences of care.

Data Linkage Project: This study will link the prospective trial cohort and the historical comparator cohort to the National Health Data Hub (NHDH). The NHDH is an enduring linked data asset that includes individual-level data from state and territory hospitals, MBS, PBS, and National Death Index.

 

Study Status 

Active, ongoing recruitment